Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Molecular Diagnostics, UCLA Plan Melanoma Test in 06

NEW YORK, Dec. 7 (GenomeWeb News) - CombiMatrix Molecular Diagnostics and researchers at the University of California, Los Angeles plan to use CombiMatrix's microarray technology to create a diagnostic for malignant melanoma.

 

The UCLA group, led by Scott Binder at the Department of Pathology and Laboratory Medicine at the Geffen School of Medicine, will work with CMD using routinely prepared formalin-fixed paraffin-embedded material. Binder's team will also provide clinically validated patient samples for the validation phase of the project.

 

The test is aimed at helping pathologists discriminate between atypical pigmented moles and malignant melanoma, CMD and UCLA said.

 

Matt Watson, CEO of CMD, said that if his firm can "gain CLIA certification in early 2006, and [its] development efforts proceed as planned, [CMD hopes] to have this test available to physicians and patients by the middle of 2006."

 

Separately, CMD this week announced plans to offer a DNA-based microarray service to identify types of influenza. The company is a wholly-owned subsidiary of CombiMatrix, which formed the company last May.

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.